Greg Verdine will have many new C-suite friends at fungus biotech LifeMine after GSK-fueled $175M round

Kyle LaHucik

Senior Reporter

A year after securing funds from Rick Klausner and adding Nobel laureate William Kaelin to the board, fungus-focused LifeMine Therapeutics is ready to reveal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Greg Verdine will have many new C-suite friends at fungus biotech LifeMine after GSK-fueled $175M round

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Greg Ver­dine will have many new C-suite friends at fun­gus biotech LifeM­ine af­ter GSK-fu­eled $175M round

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Greg Verdine will have many new C-suite friends at fungus biotech LifeMine after GSK-fueled $175M round

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.